BHVN Biohaven Pharmaceutical Holding Company Ltd.

+0.55  (+1%)
Previous Close 50.85
Open 51
Price To Book 15.07
Market Cap 2275100621
Shares 44,262,658
Volume 116,125
Short Ratio 6.64
Av. Daily Volume 453,897

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 trial enrolling.
Obsessive compulsive disorder (OCD)
NDA acceptance announced November 25, 2018. PDUFA date not supplied. Estimate July 12, 2018.
Amyotrophic lateral sclerosis (ALS)
Phase 3 completion due 2Q 2019.
Migraine - preventative
NDA filing due 2Q 2019.
Zydis ODT formulation of rimegepant
Phase 2 data futility analysis 4Q 2019.
Alzheimer’s disease
Phase 3 trial to be initiated 3Q 2019.
Multiple system atrophy (MSA)
Phase 3 commencement of enrolment announced February 20, 2019.
Generalized anxiety disorder (GAD)
Phase 3 trial to be initiated 3Q 2019.
Multiple system atrophy (MSA)
Phase 2/3 trial to be initiated 1Q 2019.
Acute treatment of migraine
Phase 3 commencement of enrolment announced March 14, 2019.
Spinocerebellar Ataxia (SCA)

Latest News

  1. Biohaven Secures Priority Review Voucher (PRV) To Expedite Regulatory Review Of Rimegepant Zydis ODT New Drug Application
  2. Biohaven Pharmaceutical Holding Co Ltd (BHVN) CEO Vlad Coric Sold $5 million of Shares
  3. Has Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Got Enough Cash?
  4. Biohaven Enrolls First Patient In Phase 3 Spinocerebellar Ataxia Clinical Trial Of Troriluzole
  5. Biohaven Announces Completion of Pre-NDA Meeting With FDA for Oral CGRP Receptor Antagonist Rimegepant
  6. Factors of Influence in 2019, Key Indicators and Opportunity within Expedia Group, Lumentum, Patterson Companies, Allscripts Healthcare Solutions, AtriCure, and Biohaven Pharmaceutical Holding — New Research Emphasizes Economic Growth
  7. Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial And Recent Business Results
  8. What Makes Biohaven Pharmaceutical Holding Company Ltd. (BHVN) a Strong Momentum Stock: Buy Now?
  9. Biohaven Enrolls First Patient In Phase 3 Generalized Anxiety Disorder (GAD) Trial Of Troriluzole
  10. Biohaven's Verdiperstat Receives Orphan Drug Designation From FDA For Multiple System Atrophy
  11. Biohaven Achieves Targeted Therapeutic Exposures of BHV-3500, a Third-Generation Small Molecule CGRP Receptor Antagonist
  12. The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study
  13. Biohaven Receives FDA May Proceed Letter For Phase 3 Clinical Trial Of BHV-3241 For Multiple System Atrophy
  14. Biohaven Announces Acceptance Of Investigational New Drug (IND) Filing For Rimegepant In China
  15. Detailed Research: Economic Perspectives on Biohaven Pharmaceutical Holding, Air Transport Services Group, Pattern Energy Group, First Solar, Limelight Networks, and Adamis Pharmaceuticals — What Drives Growth in Today's Competitive Landscape
  16. Biohaven Announces Closing Of $144M Public Offering Of Common Shares, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares
  17. Biohaven Announces Pricing of Public Offering of Common Shares
  18. Biohaven Announces Proposed Public Offering of Common Shares
  19. Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study
  20. Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Rapid and Lasting Benefit for the Acute Treatment of Migraine